Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Friday, October 1, 1999 Published at 11:15 GMT 12:15 UK


Health

Anti-flu drug rejected for NHS use

The new drug costs £24 a time

Patients will not be able to get a revolutionary anti-flu drug on the NHS, according to drug industry sources.


The BBC's Daniel Sandford: "It seems the Institute has rejected the drug at the first stage of the process"
The health watchdog responsible for assessing new treatments is reported to have concluded that there is not enough evidence that the Relenza drug is cost-effective.

Relenza - a powder-spray inhaled through the mouth - is produced by the Glaxo Wellcome company.

And the company, which could take legal action over the decision, is said to be infuriated by the move.

The drug is said to reduce the length and severity of flu if taken at the right time.

But at £24 a time, there are fears it could overwhelm local NHS budgets.


Dr George Rae from the British Medical Association: "Prevention is better than cure"
The National Institute for Clinical Excellence, which was set up by Health Secretary Frank Dobson to assess new treatments, is set to report that there is not enough evidence to show that the drug is effective with the groups at which it was to be targeted, such as the elderly.

The company can appeal against the recommendation, and a spokesman said discussions were continuing.

Difficult dilemma

Relenza is already available in New Zealand and Australia, and is due to be launched in Germany on Friday.


[ image: Glaxo Wellcome says discussions over the decision are continuing]
Glaxo Wellcome says discussions over the decision are continuing
The final decision will rest with Mr Dobson, and the case presents him with a difficult dilemma.

If he accepts the institute's recommendation, he could face accusations of rationing. But if he rejects the finding, he could damage the credibility of a body he created.

The decision is seen as the first big test of the institute, which wants more information before it will recommend the drug.

There were indications a month ago that there could be trouble ahead over the new drug.

Government advisors warned that it could cost the NHS approximately £115m if there is a flu epidemic.

GP concern

The National Prescribing Centre said in a bulletin to health service managers that Relenza could "increase expectation dramatically".


The BBC's Fergus Walsh: "The first drug to be considered by the NICE"
The document predicted that 4.8 million people could need the drug during an epidemic year.

Doctors' organisations have also warned about the dangers posed by the drug.

During the last flu epidemic, in the winter of 1989/90, 600 people in every 100,000 went to see their doctor with flu.

And it is feared that many more people will visit their GPs to demand the new treatment if it is available on the NHS.

Dr George Rae, chairman of the British Medical Association's GP's prescribing committee, said: "What we would hope is that the government will now alleviate the concerns that GPs have about Relenza.

"There could be a huge impact on GP's workload if it was freely available, as patients have to be seen within the first two days."

A NICE spokesman said that its recommendation would be made public in the next month.



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©


Health Contents

Background Briefings
Medical notes

Relevant Stories

01 Oct 99†|†Health
Relenza: the implications

01 Oct 99†|†Health
Relenza: the reaction

06 Aug 99†|†Health
NHS rationing: The key areas

02 Sep 99†|†Health
Cost warning on flu drug

06 Aug 99†|†Health
NHS agenda for expensive drugs

18 Feb 99†|†Medical notes
Flu: The facts

31 Mar 99†|†Health
NICE: A fundamental change





Internet Links


Glaxo Wellcome

Department of Health

Influenza information

National Prescribing Centre

National Institute for Clinical Excellence


The BBC is not responsible for the content of external internet sites.




In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99